Orbimed Advisors LLC Aerovate Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.68 - $29.57 $3.39 Million - $5.66 Million	-191,556 Reduced 25.31%	565,374 $16.7 Million
Q1 2023 May 15, 2023	SELL	$19.17 - $27.7 $50,033 - $72,297	-2,610 Reduced 0.34%	756,930 $15.3 Million
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $564,523 - $1.08 Million	-35,460 Reduced 4.46%	759,540 $22.3 Million
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $4.67 Million - $8.16 Million	316,421 Added 66.12%	795,000 $13.2 Million
Q2 2022 Aug 15, 2022	SELL	$10.8 - $16.91 $338,796 - $530,466	-31,370 Reduced 6.15%	478,579 $7.48 Million
Q1 2022 May 16, 2022	SELL	$8.25 - $18.33 $212,561 - $472,272	-25,765 Reduced 4.81%	509,949 $9.35 Million
Q2 2021 Aug 16, 2021	BUY	$22.83 - $22.83 $12.2 Million - $12.2 Million	535,714 New	535,714 $12.2 Million

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $61.9M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.